

Professor Lian-Sheng Ma

President and Company Editor-in-Chief Baishideng Publishing Group  
*World Journal of Gastrointestinal Oncology*

Dear Professor Lian-Sheng Ma

Manuscript: 62648

“Molecular-targeted therapy toward precision medicine for gastrointestinal cancer:  
Current progress and challenges”, by Tasuku Matsuoka and Masakazu Yashiro

We are most grateful to you and the reviewers for the helpful comments and have addressed each concern with either new data or modification of the manuscript text. We check the reviewer's comments and revised the sentences mainly of higher part.

Thank you for your kind attention.

Best regards.

Sincerely yours

Tasuku Matsuoka, M.D., Ph. D.

## Reviewers' comments to the authors

### **Reviewer #1:**

The manuscript clarifies the current evidence for targeted therapies in GI cancer by evaluating the latest data regarding anti-EGFR, HER2, VEGF, PI3K/AKT, TGF- $\beta$ , MET, WNT, PARP and immunotherapies. And Targeting these molecules will improve the outcomes of patients with GI cancer. The review concept is clear. And the manuscript is well and concisely written. However, English editing is required.

*Response: We appreciate the reviewer's comments. We have checked the entire manuscript and rewritten carefully to correct English grammar and spelling and to make the manuscript as clear as possible along the reviewer's recommendation.*

### **Reviewer #2:**

The content of the review is very comprehensive, which summarizes the advancement of precision medicine in GI cancer. The first part named "targeting the RAS / Raf / MEK pathway" seems not proper, why not named it "targeting EGFR"? Maybe this title is more consistent with the following figures and tables.

I believe it is necessary to properly introduce the relationship between RAS / Raf / MEK pathway and EGFR.

It seems that the writing style of this part is not consistent with that of the following parts.

*Response: We appreciate the reviewer's comments. According to the reviewer's suggestion, we reword "targeting the RAS / Raf / MEK pathway" to "targeting EGFR" and introduced the relationship between RAS / Raf / MEK pathway and EGFR.*